Study #2022-0172
Managing Agitated Delirium with Neuroleptics and anti-Epileptics as a Neuroleptic Sparing Strategy
MD Anderson Study Status
Enrolling
Treatment Agent
Haloperidol, Chlorpromazine, Valproate, Placebo
Description
To examine the effects of haloperidol, chlorpromazine, valproic acid and placebo, in conjunction with standardized non-pharmacologic interventions, in the first line treatment of agitated delirium in hospitalized patients with cancer. This double-blind, randomized clinical trial aims to provide evidence on various therapeutic options for palliating delirium, thereby reducing delirium-related distress and ultimately alleviating suffering.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Delirium, Epileptics, Neuroleptics
Study phase:
Phase II/III
Physician name:
David Hui
Department:
Palliative Care & Rehabilitation Medicine
For general questions about clinical trials:
1-855-900-1058
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.